

PRECEPTORSHIP PROGRAMME

Immuno-Oncology

From the essentials of tumour
immunology to clinical application

SINGAPORE

20-21 NOVEMBER 2019

Co-Chairs

Boon Cher Goh, SG

John B.A.G. Haanen, NL

ESMO PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY

From the essentials of tumour immunology to clinical application

Singapore
20-21 November 2019

CO-CHAIRS:

Boon Cher Goh, Singapore
John B.A.G. Haanen, Netherlands

SPEAKERS:

Anthony T. C. Chan, Hong Kong
Cheng Ean Chee, Singapore
Jayesh Desai, Australia
Alena Gros, Spain
Ravindran Kanesvaran, Singapore
Sung-Bae Kim, South Korea

Soo Chin Lee, Singapore
Kenneth J. O'Byrne, Australia
Solange Peters, Switzerland
Michele Teng, Australia
Baiyan Wang, China

LEARNING OBJECTIVES

- To understand the basics of tumour immunology
- To learn about the essentials of immunotherapies and their present indication in cancer treatment
- To learn about the status of development and clinical experience of immunotherapy in different tumour types

ACCREDITATION

The programme of this event has been accredited with **10 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Wednesday, 20 November 2019

09:00-09:10 10'	Welcome	Boon Cher Goh, SG John B.A.G. Haanen, NL
09:10-10:40 90'	SESSION 1 - Introduction	
20'	History of cancer immunology and immunotherapy	John B.A.G. Haanen, NL
30'	Principles of tumour immunology: Explaining cellular immunity and immune surveillance	Michele Teng, AU
25'	Principles of cancer immunotherapy	Alena Gros, ES
15'	Discussion	Faculty
10:40-11:10	Coffee break	
11:10-12:45 95'	SESSION 2 - Recent advances with ICPI: Results in approved / unapproved indication (Part 1)	
30'	Melanoma advanced and adjuvant	John B.A.G. Haanen, NL
30'	Non-Small-Cell Lung Cancer	Solange Peters, CH
20'	Gynaecological malignancies and breast cancer	Soo Chin Lee, SG
15'	Discussion	Faculty
12:45-13:45	Lunch	
13:45-15:25 100'	SESSION 3 - Clinical issues	
20'	Assessment of efficacy	Kenneth J. O'Byrne, AU
20'	Immune related toxicities and management	John B.A.G. Haanen, NL
30'	Biomarkers: PD-L1 and beyond PD-L1	Boon Cher Goh, SG
20'	Cost of immuno-oncology treatment	Solange Peters, CH
10'	Discussion	Faculty
15:25-16:00	Coffee break	
16:00-17:15 75'	SESSION 4 - Recent advances with ICPI: Results in approved / unapproved indication (Part 2)	
20'	Oesophageal, gastric and colorectal cancer	Jayesh Desai, AU
20'	Hepatocellular carcinoma	Cheng Ean Chee, SG
20'	Head and neck cancer	Anthony T. C. Chan, HK
15'	Discussion	Faculty
17:15-17:55 40'	SESSION 5 - Audience cases	
40'	Participants clinical case discussion (4x10')	Faculty
19:30	Dinner	

Thursday, 21 November 2019

08:30-09:10 40'	SESSION 6 - Recent advances with ICPI: Results in approved / unapproved indication (Part 3)	
30'	Advanced urinary cancer (renal and bladder)	Ravindran Kanesvaran, SG
10'	Discussion	Faculty
09:10-10:30 80'	SESSION 7 - Audience cases	
80'	Participants clinical case discussion (8x10')	Faculty
10:30-11:00	Coffee break	
11:00-12:00 60'	SESSION 8 - Future of immuno-oncology	
25'	CAR T-Cell therapy	Baiyan Wang, CN
25'	Combination therapy	Sung-Bae Kim, KR
10'	Discussion	Faculty
12:00-12:10 10'	Closure and farewell	Boon Cher Goh, SG John B.A.G. Haanen, NL
12:10-13:10	Lunch	

Note: Each 10 minute slot for clinical case discussion includes 5' case presentation and 5' Q&A / panel discussion